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Abstract 
 
Background: An emerging problem in the treatment of breast cancer is the increasing 
incidence of metastases to the brain. Metastatic brain tumours are incurable and can cause 
epileptic seizures and cognitive impairment, so better understanding of this niche, and the 
cellular mechanisms, is urgently required. Microglia are the resident brain macrophage 
population, becoming “activated” by neuronal injury, eliciting an inflammatory response. 
Microglia promote proliferation, angiogenesis and invasion in brain tumours and metastases. 
However, the mechanisms underlying microglial involvement appear complex and better 
models are required to improve understanding of function.  
Methods: Here, we sought to address this need by developing a model to study metastatic 
breast cancer cell-microglial interactions using intravital imaging combined with ex vivo 
electrophysiology. We implanted an optical window on the parietal bone to facilitate 
observation of cellular behaviour in situ in the outer cortex of heterozygous Cx3cr1GFP/+ mice. 
Results: We detected GFP-expressing microglia in Cx3cr1GFP/+ mice up to 350 µm below the 
window without significant loss of resolution. When DsRed-expressing metastatic MDA-MB-
231 breast cancer cells were implanted in Matrigel under the optical window, significant 
accumulation of activated microglia around invading tumour cells could be observed. This 
inflammatory response resulted in significant cortical disorganisation and aberrant 
spontaneously-occurring local field potential spike events around the metastatic site.  
Conclusions: These data suggest that peritumoral microglial activation and accumulation 
may play a critical role in local tissue changes underpinning aberrant cortical activity, which 
offers a possible mechanism for the disrupted cognitive performance and seizures seen in 
patients with metastatic breast cancer. 
 
Keywords: Breast cancer / Electrophysiology / Intravital imaging / Metastasis / Microglia 
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Introduction 
 
Metastasis, the spreading of primary tumours to secondary sites, is responsible for 90 % of 
deaths from cancer and is a leading cause of morbidity in cancer patients (1). The incidence 
of breast cancer patients developing brain metastases is increasing, particularly for those 
with tumours that are human epidermal growth factor 2 (HER2) positive or triple negative 
(TN; lacking HER2, progesterone and oestrogen receptor) (2, 3). Most breast cancer brain 
metastases occur in the frontal lobe, with cerebellum and parietal lobe also being common 
sites (4). The majority are characterised as parenchymal brain metastasis, with 10-20 % 
occurring as leptomeningeal metastasis (5). Treatment options are mainly limited to whole 
brain radiation, in some cases neurosurgery, and survival is poor (6, 7). Furthermore, 
patients with metastatic brain tumours present with neurological symptoms including 
cognitive impairment and epileptic seizures (8, 9), and this can have a significant impact on 
quality of life. However, the pathophysiological mechanisms underlying the cause of 
neurocognitive impairment and tumour-associated epilepsy are poorly understood (10-12). 
Thus, there is an urgent need to better understand the mechanisms regulating seeding and 
expansion of brain metastases and their neurological sequelae in order to develop new 
effective therapies. 
 
As is the case with primary tumours, the heterogeneous microenvironment is thought to play 
a key role in progression of metastatic disease (13). In the context of the neural niche, the 
heterotypic contributions of a range of cell types has been identified, including microglia. 
Microglia are the resident innate immune (macrophage) population in the brain and play a 
key role in neuroinflammatory processes. At steady state, microglia undertake a surveillance 
role, becoming “activated” following neuronal injury or infection (14). Microglial activation 
drives the neuroinflammatory responses that underpin neuronal loss and dysfunction in 
neurodegeneration, affective disorders, stroke and brain tumours (15-18). Under normal 
physiological conditions in vivo, microglia adopt a highly mobile ramified morphology, 
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constantly scanning the brain parenchyma for injury to neuronal circuitry. Upon detection of 
a lesion, activated microglia rapidly undergo targeted migration to the injury site where they 
orchestrate an inflammatory response (19). Activated microglia are the main immune 
population clustering around brain metastases in mouse models and patient brain tissue 
(20). 
 
The involvement of microglia in progression of metastases is complex and dependent on 
programming by the local brain tumour microenvironment (18). Microglia interact with 
metastatic breast cancer cells in a heterogeneous fashion in mouse models, adopting 
multiple morphological states related to diverse functional contributions to tumour 
progression (20). The spectrum of activated microglial phenotypes in brain tumours ranges 
from “classical” M1 proinflammatory cells capable of releasing proinflammatory cytokines 
and eliciting a T cell response, to “alternative” M2 anti-inflammatory cells which promote 
tumour growth, angiogenesis and invasion (21-25). Thus, targeting the anti-inflammatory 
microglial population (26-28), and/or enhancing the activity of the proinflammatory 
population (29), may provide a new treatment approach for brain metastases. However, 
better models are required to improve understanding of the functional activity of microglia in 
the microenvironment around brain tumour cells. 
 
Intravital two-photon imaging represents a useful tool for studying cellular activity in the 
microenvironment of tumours in three dimensions and over time (30). Using this technique, it 
is possible to visualise tissue structures at cellular resolution in order to understand 
mechanisms underlying cell-cell interactions and invasion. Intravital imaging approaches 
using orthotopic breast tumour models have provided important insights into the 
mechanisms underlying migration and invasion as well as improving understanding of 
tumour heterogeneity (31-34). In the context of brain tumours, intravital imaging has been 
used to visualise glioma proliferation and invasion, as well as response to anti-tumour 
therapies (35). Intravital imaging has also been employed to study microglial activation (14, 
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36). However, the approach has not been previously used to directly study the interaction 
between breast cancer cells and microglia in the brain metastatic niche. In the present study, 
we sought to address this gap by developing a model to study breast tumour-microglial 
interactions using intravital imaging combined with ex vivo electrophysiology. Using this 
approach, it was possible to visualise microglial activation and accumulation, cortical 
disorganisation and aberrant spontaneous electrical activity around the lesion site. 
 
Materials and Methods 
 
Cell culture 
 
MDA-MB-231 cells were maintained in Dulbecco’s modified eagle medium (DMEM) 
supplemented with 5 % FBS and 4 mM L-glutamine (37). The cells were stably transduced 
with recombinant lentivirus for DsRed (gift from M. Lorger, University of Leeds). Cells were 
confirmed as mycoplasma-free using the DAPI method and their molecular identity was 
confirmed by short tandem repeat analysis. 
 
Animals 
 
Female heterozygous Cx3cr1GFP/+ mice on a C57BL/6 (B6) background (obtained from the 
Jackson Laboratories, Bar Harbour, USA) were used for all experiments in this study (38). 
Animals were maintained on a 12 h light/dark cycle with food/water ad libitum. Animal 
procedures were performed following approval from the University of York Animal Welfare 
and Ethical Review Body and under authority of a UK Home Office Project Licence. Surgical 
procedures were performed within the regulations of the UK Animals (Scientific Procedures) 
Act, 1986. Experiments have been reported in accordance with the ARRIVE guidelines. 
 
Cranial window installation and implantation of tumour cells 
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The installation of a cranial imaging window was based on procedures described previously 
(39). Mice (8-17 weeks old; n = 23) were anaesthetised using isoflurane and the head was 
stabilised in a stereotaxic frame (Kopf Instruments). Cerebral oedema was treated peri-
operatively with dexamethasone (2 µg/g body weight; intramuscular injection). Post-surgical 
inflammation was treated peri-operatively and at 24 h intervals for 3 days followed by 48 h 
intervals for 2 weeks after surgery with carprofen (5 µg/g body weight; subcutaneous 
injection) and buprenorphine (0.1 µg/g body weight; subcutaneous injection). A small (3 mm 
diameter) craniotomy was performed on the left parietal bone above the posterior parietal 
cortex (centred 2.5 mm posterior to Bregma, 2 mm lateral to midline). In some animals, 
MDA-MB-231-DsRed cells (104 suspended in 20 % v/v Matrigel in saline to maintain a single 
focused drop) were placed on the exposed area, without removing the meninges, using a 
pipette. A 4 mm diameter round No. 1 glass coverslip (Menzel-Gläser) was then placed onto 
the surgical area, mounted onto the surrounding skull using Vetbond tissue adhesive and 
sealed in place with dental cement. A small 4 mm x 8 mm titanium plate was attached to the 
skull using tissue adhesive as an aid for future stabilisation of the head during imaging. 
Animals were allowed to recover for 5 days before imaging. Weight and body condition were 
monitored at regular intervals following surgery. Mice were re-grouped following recovery 
from surgery and were maintained for varying durations up to 1 month following surgery to 
allow for serial imaging. At the end of the imaging period, mice were humanely killed and 
brain tissue was harvested for electrophysiological recording and/or immunohistochemistry. 
 
Microscope set-up 
 
We used a Zeiss LSM 780 multiphoton fitted to an AxioObserver Z1 inverted microscope 
and coupled to a Coherent Chameleon Ultra Ti-Sapphire 2-photon laser with the stage 
sitting within a Solent Scientific temperature-controlled light-tight box. An InverterScope 
(LSM Tech, Etters, PA) objective inverter was used to convert the system to an upright 
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configuration and enable positioning of the W Plan Apochromat 20x/1.0 NA objective lens 
above the cranial window. The inverter was purpose adapted, with the addition of a reflective 
interior and MaxMirror dielectric mirrors, to maximise excitation and emission transmission at 
both visible and far-red wavelengths (>900 nm). The excitation power exiting a Plan 
Apochromat 20x/0.8 objective was monitored a priori using a Coherent Fieldmate power 
meter and Coherent OP-2 vis sensor (488 nm) or a PM2 sensor (920 nm) for a range of % 
transmissions with and without the InverterScope. A standard control sample (Molecular 
Probes FluorCell slide #6) was used to compare Alexafluor 488 emission back through to 
the detectors with and without the InverterScope after excitation at either 488 nm or 920 nm.!
 
Intravital imaging 
 
Mice were anaesthetised for restraint using ketamine (100 µg/g body weight) and xylazine 
(10 µg/g body weight) prior to imaging and placed on their ventral side on the heated 
microscope stage. The head was stabilised with an in-house custom-made holder to 
minimise motion artefacts. The light-tight box was pre-warmed to 37 ˚C and was maintained 
at this temperature for the duration of the imaging session (typically less than 1 h). GFP and 
DsRed were visualised using two-photon excitation at 920 nm and emission detected via a 
500-550 nm band pass filter for GFP and 550 nm long pass filter for DsRed. Images were 
acquired sequentially and saved for offline processing using Zeiss Zen2 software. The laser 
power used was up to 15 mW post-objective, dependent on experiment. 
 
Electrophysiology 
 
Coronal slices (450 µm thick) were prepared from the region of the brain under the imaging 
window, and the contralateral equivalent, at the end of the intravital imaging period (i.e. after 
>13 days following implantation of the tumour cells). Slices were maintained in an interface 
chamber at 34 °C in oxygenated (95 % O2/5 % CO2) artificial cerebrospinal fluid (ACSF) 
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consisting of (in mM): 126 NaCl, 3 KCl, 1.25 NaH2PO4, 0.6 MgSO4, 1.2 CaCl2, 24 NaHCO3 
and 10 glucose, with neuromodulatory conditions associated with wake state modelled by 
inclusion of 15 µM carbachol. Extracellular recordings were obtained using micropipettes (2-
5 MΩ) filled with ACSF and were bandpass filtered at 0.1 Hz to 300 Hz. 
 
Immunohistochemistry and confocal microscopy 
 
For tissue preparation and immunohistochemistry mice underwent terminal anaesthesia and 
perfusion fixation with 4 % paraformaldehyde. Brains (or slices, following termination of 
electrophysiological experiments) were placed in fixative at 4 ˚C for >48 h and were then 
washed and sectioned at 20-60 µm. Control mammary tumour and naïve spleen sections 
were from tissue collected as part of other studies (37). The following primary antibodies 
were used as described previously (40): rabbit anti-Iba1 (1:500; Fujifilm Wako Chemical 
Corporation), mouse anti-human nuclear antigen (1:100; Merck), Alexa Fluor 647-
conjugated rat anti-CD45 (1:100; Biolegend), and rabbit anti-TMEM119 (1:100; Abcam). 
TMEM119 staining required antigen retrieval and slices were incubated at 90 ˚C for 15 min 
in 10 mM Citrate Buffer (pH 6) containing 0.05 % Tween-20. The secondary antibodies were 
Alexa Fluor 488/633-conjugated goat anti-rabbit/mouse, as appropriate (1:500; Molecular 
Probes). Sections were counter-stained with Hoechst 33258 and mounted in VectaShield 
(Vector Laboratories) or Prolong Gold (Molecular Probes). Images were acquired using a 
Zeiss AxioObserver Z1 microscope fitted with W Plan Apochromat 20x/1.0 NA and 63x 
oil/1.0 NA objective lenses and LSM 880 laser scanner. Images were acquired sequentially 
and saved for offline processing using Zeiss Zen2 software.  
 
Image processing and Sholl analysis 
 
Images were imported into the Fiji distribution of ImageJ for processing using the LSM 
Toolbox plugin. Brightness and contrast were adjusted using the Fiji “auto” function. Imaging 
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depth (µm) was determined relative to that of superficial-most image for each acquisition 
session. Sholl analysis (41, 42) was performed on imported images as follows: First, 
arborisation paths on individual microglia (≤ 10 cells/image) were traced using the Simple 
Neurite Tracer plugin. Next, trace profiles were processed using the Sholl analysis plugin. 
For each cell, the number of processes intersecting concentric radii, centred on the nucleus, 
was recorded at 2 µm intervals and averaged to produce a Sholl plot (41). In addition, the 
maximum number of intersections per radius, maximum branch length (largest radius 
intersecting a branch), number of primary branches originating from the soma, and 
Schoenen ramification index (ratio of maximum number of intersections per radius and 
number of primary branches) were calculated (42, 43). The number of direct interactions 
between tumour cells and microglia (where one cell visibly touches another) was counted 
and divided by the number of tumour cells for a given field of view (44). 
 
Statistical analysis 
 
Data are presented as mean and SEM unless stated otherwise. Statistical analysis was 
performed using GraphPad Prism 7. Distribution was evaluated using D’Agostino-Pearson 
normality test. Statistical significance was determined with Mann-Whitney tests for pairwise 
comparisons and ANOVA followed by Sidak’s tests or Kruskal-Wallis followed by Dunn’s 
tests for multiple comparisons, as appropriate. Results were considered significant at P < 
0.05. 
 
Results 
 
Validation of intravital multiphoton imaging method 
 
It was necessary to purpose-adapt our two-photon Zeiss LSM 780 microscope with an 
objective inverter to permit intracranial imaging. We therefore first tested the effect of the 
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customized InverterScope on imaging performance. We confirmed that there was minimal 
loss of 488 nm and 920 nm excitation power exiting a Plan Apochromat 20x/0.8 objective 
with the InverterScope in place (Supplementary Figure 1A). There was also no impact on 
evenness of illumination across the field (data not shown). Using a standard fluorescent 
sample there was only a 15 % loss in emission at the internal detectors after 488 nm 
excitation and a 7 % loss in emission at the non-descanned detectors after 920 nm 
excitation compared to without the InverterScope (P < 0.001; Supplementary Figure 1B, C). 
 
Given that the modified InverterScope only resulted in minimal (7 %) loss of detected 
emission, we next used the experimental setup to image GFP-expressing microglia in 
Cx3cr1GFP/+ mice. In the initial pilot study and technique development, animals were killed 
prior to window implantation and imaging (Supplementary Figure 2A). We evaluated 
implantation of the optical window on the parietal bone, close to the lambdoid and sagittal 
sutures, as the best method for examining cellular morphology in situ in the outer cortex, 
taking into account the potential need for repeated imaging of the same animal. This 
approach enabled us to detect GFP-expressing microglia in Cx3cr1GFP/+ mice up to 250 µm 
below the window using a laser power of 6 mW (as measured at the objective) without 
significant loss of resolution (Supplementary Figure 2Bi-iii). By increasing the laser power to 
10 mW, we were able to image deeper, to depths of 350 µm, still maintaining acceptable 
resolution (Supplementary Figure 2Biv, v). This imaging approach enabled visualisation of a 
highly ramified morphology with extensive arborisations, which were indistinguishable from 
those visualised in Iba1-stained sections using confocal microscopy (Supplementary Figure 
2Bvi). In order to accurately determine the effect of imaging depth on visualisation of key 
parameters of microglial morphology, we next quantified the extent of arborisation of 
microglial processes using Sholl analysis (41, 42). Analysis of microglial arborisations 
acquired at different imaging depths revealed typical branching profiles, equivalent to those 
reported previously for ramified microglia (Supplementary Figure 2C) (45). There was a 
small shift to the left in the branching profiles for microglia imaged at depths >150 µm, 
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indicating a slight decrease in branching with increased distance from the soma, perhaps 
due to a small loss in resolution and imaging sensitivity at greater depths up to 350 µm. 
However, the maximum branch length (maximum radius intersecting a branch) and 
Schoenen ramification index were unchanged across the range of imaging depths tested (P 
= 0.11 and 0.43, respectively; n = 10 microglia/imaging depth; Supplementary Figure 2D, E). 
Together, these data suggest that, using the InverterScope, it is possible to reliably detect 
arborisations in ramified microglia at imaging depths up to 350 µm. 
 
Microglia are highly ramified at steady state in vivo 
 
In order to study the ramification of microglia in steady state, we next imaged GFP-
expressing microglia in live anaesthetised Cx3cr1GFP/+ mice, after implantation of the optical 
window (Supplementary Figure 3A). As with the post mortem imaging, we were able to 
visualise GFP-expressing microglia in Cx3cr1GFP/+ mice to depths up to 350 µm, maintaining 
acceptable resolution (Supplementary Figure 3B). There was some minor loss of image 
quality compared to post mortem imaging likely as a result of pulse pressure artefacts. 
Second harmonic generation (SHG) imaging revealed that collagen signal was largely 
absent in the cortical parenchyma (data not shown), consistent with previous reports (35). 
Quantification of microglial arborisations using Sholl analysis revealed a typical branching 
pattern, similar to that calculated for post mortem images (Supplementary Figure 3C). In 
addition, the maximum branch length was unchanged across the range of imaging depths 
tested in vivo (P = 0.14; n ≥ 10 microglia/imaging depth; Supplementary Figure 3D). 
Similarly, the Schoenen ramification index was not significantly different across the same 
range of imaging depths (P = 0.36; n ≥ 10 microglia/imaging depth; Supplementary Figure 
3E). Importantly, the maximum number of intersections per radius, maximum branch length, 
and Schoenen ramification index were unchanged in the in vivo imaged animals compared 
to post mortem imaged animals (Supplementary Table 1), consistent with any reduction in 
image quality in vivo not precluding detection or measurement of processes. In summary, 
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these data suggest that visualisation of GFP-expressing microglia in anaesthetised live 
animals permits broadly similar measurement of microglial arborisation to post mortem 
imaging. 
 
Microglia interact with metastatic breast cancer cells 
 
A growing body of evidence indicates that microglia promote tumour progression (20). For 
example, microglia have been shown to increase brain colonisation by breast cancer cells 
via a mechanism that requires Wnt signalling (46). In order to gain deeper mechanistic 
understanding of the processes involved, better models are needed to study microglial 
behaviour in the presence of metastatic cancer cells. We therefore next adapted this model 
to study tumour cell-microglial interactions in vivo. We implanted 1 x 104 DsRed-expressing 
MDA-MB-231 metastatic breast cancer cells suspended in Matrigel on the exposed dura 
mater of Cxcr31GFP/+ mice, under the imaging window coverslip at time of surgery. We then 
imaged GFP-expressing microglia and DsRed-expressing breast cancer cells in 
anaesthetised mice, at various time points following recovery from surgery (Figure 1A). 
Using this approach, we were able to visualise invasion of tumour cells into the cortical 
parenchyma, together with recruitment of microglia to the lesion site at 5- and 7-days post 
implantation (Figure 1B). Consistent with this, we observed microglia surrounding and 
directly interacting with tumour cells (Figure 1B, arrowheads). These interactions were 
evident across all animals studied (additional examples are in Figure 1C and a 3-D image is 
in Supplementary Figure 4). The number of microglial interactions per breast cancer cell 
significantly increased between 5- and 7-days post implantation (P < 0.001; n = 8 fields of 
view/time point; Figure 1D). In addition, the density of GFP-positive cells was significantly 
higher in fields of view containing tumour cells compared to animals in which no tumour cells 
had been implanted (P < 0.01; n ≥ 5 fields of view/condition; Figure 1E). Sholl analysis of 
microglial arborisations revealed that the presence of tumour cells notably reduced the 
number of branches compared to control animals (Figure 1F). Similarly, the maximum 
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branch length and Schoenen ramification index were significantly reduced in the presence of 
cancer cells (P < 0.01 for both; n ≥ 20 microglia/condition; Figure 1G, H). Importantly, 
implantation of Matrigel alone without tumour cells had no effect on microglial morphology 
(Supplementary Figure 5). Together, these data suggest that implantation of metastatic 
breast cancer cells induces activation and accumulation of GFP-expressing microglia. 
 
Persistent alteration of tissue architecture and electrical activity following tumour cell 
implantation 
 
The accumulation of microglia to the lesion site, which started from 5 days, was maintained 
at 9- and 13-days post implantation (Figure 2A-C). In particular, there was notable 
accumulation of GFP-positive cells at the periphery of the lesion (Figure 2A, arrows). 
Interestingly, however, there were significantly fewer DsRed-positive tumour cells at 9 and 
13 days, suggesting that the microglial-induced immune response was capable of clearing 
the tumour cells from the lesion site (P < 0.001; n = 8 fields of view/time point; Figure 2B-D). 
In agreement with this observation, ex vivo confocal imaging of tissue sections at the end of 
the experiment revealed that although some DsRed-expressing tumour cells (44 ± 14 
cells/mm2) were still present superficially, none were detectable deeper into the tissue 
(Figure 3A, B, arrowheads). Similarly, sections stained with an anti-human nuclear antigen 
antibody showed an absence of tumour cells at the lesion site (Figure 4). However, we were 
able to detect punctate acellular DsRed signal adjacent to, or within some GFP-expressing 
cells, consistent with the possibility that the microglia had destroyed and engulfed some of 
the tumour cells (Figure 3A-C, arrows). In addition to microglia, CX3CR1 is also expressed 
on macrophages, certain subtypes of T cells and natural killer cells (38, 47, 48), raising the 
possibility that some of the GFP-positive population at the lesion site may constitute other 
cell types. The microglia-specific marker TMEM119 (49) was expressed on ramified 
microglia in control brain parenchyma and there was also strong staining at the lesion site 
(Figure 5A, B). This staining pattern was replicated using a second microglial marker, Iba1, 
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with similar results (Supplementary Figure 6). There was some limited infiltration of CD45hi 
GFP- leukocytes at the lesion site compared to normal brain parenchyma (Figure 6A, B). 
However, the majority of GFP+ cells were CD45low or -, consistent with these cells being 
microglia (Figure 6B). Together, these data suggest that the GFP+ cells at the lesion are 
predominantly microglia. In addition, the lack of CD45hi cells suggests that there is minimal 
infiltration of other immune cells in response to the xenograft. 
 
Given the striking observation of significant and persistent microglial accumulation to the 
tumour site, we postulated that the lesion may disrupt normal cortical electrophysiological 
function. We therefore next evaluated spontaneous electrical activity in coronal tissue slices 
under the imaging window and on the contralateral side to the implantation site. 
Spontaneously-occurring local field potential spike events were observed in slices taken 
from the region of the brains underlying the tumour cell implantation sites in all cases. 
Events were only seen in superficial layers, particularly layer 2 (L2) and never seen in deep 
layers (Figure 7A) or in any layer contralateral to the inoculation site. Mean spike amplitude 
was 98 ± 6.0 µV (n = 138 events from slices from 2 mice) with 5/138 outliers where 
amplitude was >0.5 mV. Field spike durations were highly variable and non-normally 
distributed (Figure 7B). Three modal peak halfwidths were seen at 48, 111 and 215 ms. 
Morphology of the field spikes was highly dependent on recording electrode position relative 
to the lesion (Figure 7C). Within the lesion itself bursts of multi-unit activity occurred with no 
concurrent field spike. This pattern was reversed peri-annularly around the lesion wall in L2, 
with overt field spikes seen with no concurrent multi-unit activity. In summary, the imaging 
and electrophysiological data reveal that in this model there is a significant and persistent 
microglial response to the location of metastatic breast cancer cells, and although this is 
capable of removing some of the tumour cells, there remains significant disruption to normal 
electrical activity within and adjacent to the lesion site. 
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Discussion 
 
In this study, in mice expressing GFP under control of the endogenous Cx3cr1 promoter, we 
were able to visualise microglial behaviour in the cortex at a depth of up to 350 µm using 
intravital imaging without significant loss of resolution. Sholl analysis revealed that the 
arborisation of resting microglia was unchanged across the range of imaging depths tested, 
both ex vivo and in vivo. Implantation of DsRed-expressing MDA-MB-231 breast cancer cells 
under the optical window resulted in recruitment and activation of microglia to the site of 
metastatic cancer cells. The immune response cleared the majority of the tumour cells within 
9 days, but the accumulation of microglia to the lesion persisted for at least 13 days. This 
significant cortical disorganisation gave rise to aberrant spontaneously-occurring local field 
potential spike events within the tumour and peri-annularly in superficial layers. 
 
Intravital imaging of microglial morphology enables the study of cellular changes in the 
native microenvironment in real-time and thus is a critical approach to study behavioural 
changes in response to injury or infection (14, 36). Although it is possible to culture microglia 
in vitro, when removed from the brain, their behaviour changes (50) and so intravital imaging 
provides a useful means to study microglial arborisation in living cells in situ. The microglial 
behaviour captured here using intravital imaging broadly agrees with previous reports (14, 
36), together with morphological data recorded from brain tissue sections using 
immunohistochemistry (45). Quantification of microglial morphological characteristics using 
Sholl analysis reveals broadly similar arborisation profiles and Schoenen ramification indices 
to those reported in tissue sections (41, 42, 45), underscoring that there was no activation of 
microglia in the parenchyma under the imaging window as a result of the surgery or 
implantation of Matrigel alone. Furthermore, the high degree of consistency between our 
intravital imaging data and the reported ex vivo immunohistochemistry data (45) suggest that 
any loss of resolution as a result of imaging in vivo was minimal. 
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Our data demonstrate a remarkable change in microglial morphology in response to the 
presence of metastatic breast cancer cells. We observed accumulation of microglia to the 
lesion site, together with significant reduction in ramification, consistent with acquisition of an 
activated phenotype. To our knowledge, this is the first time that intravital brain imaging has 
been used to visualise the behaviour of microglia in the presence of metastatic breast 
cancer cells. The implantation site represents a leptomeningeal metastasis, which accounts 
for approximately 11-20 % of brain metastases, thus presenting a significant clinical burden 
(5). We also found significant infiltration of tumour cells into the outer cortical parenchyma 
and recruitment of microglia to the lesion, suggesting that the model may have broader utility 
for understanding tumour cell-microglial interactions in parenchymal brain metastases. The 
findings are consistent with other cortical implantation models, e.g. (35), suggesting that the 
underlying mechanisms (and microglial involvement) are likely similar. 
 
As CX3CR1 is also expressed on peripheral blood monocytes, natural killer cells and 
dendritic cells in addition to microglia (38, 47), it is possible that some of the accumulation of 
GFP-positive cells that we observed at the lesion site may be due to recruitment of other 
CX3CR1-expressing immune cells. However, the TMEM119 staining argues against this and 
suggests that there was minimal infiltration of other immune cell types. The data from our 
model agree with previous observations from mice and patients that activated microglia 
cluster around brain metastases (20), suggesting that the majority of the peritumoral GFP-
positive cells are indeed microglia. We found that the accumulation of microglia persisted for 
the 13-day duration of the experiment following implantation of the breast cancer cells. 
However, the number of intact breast cancer cells was dramatically reduced after 5 days, 
although we could still detect isolated DsRed-positive cells and punctate acellular DsRed 
fluorescence at the lesion site at the end of the experiment. This rapid clearance of the 
tumour cells may reflect, in part, a graft versus host immune response to the 
xenotransplantation of a human breast cancer cell line into an immunocompetent mouse 
(51), although there was very limited infiltration of CD45hi immune cells at the lesion site. An 
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alternative possibility is that the DsRed cells rapidly die by necrosis or apoptosis, although 
the significant disruption to the local architecture of the cortical parenchyma in the presence 
of the cancer cells would argue against this. Nonetheless, the results presented here 
suggest that imaging of microglia in the context of metastatic breast cancer cells in the brain 
may yield novel insights into their functional contribution to tumour progression (20). In 
particular, intravital imaging approaches such as this have the advantage of enabling 
visualisation of cellular changes in real-time using a system that is easy to manipulate (14, 
30, 36). 
 
Primary and metastatic brain tumours can have a range of neurological consequences such 
as headaches, mild cognitive impairment, and epileptic seizures (12). This aspect of the 
disease burden in the brain has a significant impact on quality of life and is difficult to treat 
as the mechanistic basis is poorly understood (10-12). Several mechanisms have been 
proposed to explain the presentation of tumour-associated epilepsy, including disrupted 
glutamate homeostasis, altered ion channel expression, altered network activity, and 
inflammation (52-55). We found aberrant spontaneously-occurring local field potential spike 
events local to the tumour. In addition, the activity pattern differed within the lesion 
compared to peri-annularly around the lesion wall, suggesting that changes within the 
tumour and peritumoral tissue may differentially mediate altered electrical activity. The 
altered excitability and electrical signatures observed here resemble interictal-like epileptic 
wave forms that have been associated with poor cognitive performance and have been seen 
in electroencephalograms (EEGs) of patients presenting with epilepsy (56), suggesting that 
our model may recapitulate early stages of cortical disorganisation that could subsequently 
lead to tumour-associated epilepsy. Interictal activity can be caused by alterations in 
expression and/or activity of neurotransmitter receptors and ion channels (57) to promote 
glutamatergic transmission and decrease GABAergic activity. In addition, neuronal atrophy 
and/or altered connectivity can occur in the chronic phases of rodent epilepsy models (58). 
Furthermore, the data here raise the possibility that peritumoral microglial activation and 
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accumulation may play a critical role in local tissue changes leading to aberrant cortical 
activity. 
 
Conclusions 
 
The results presented here show that it is possible to visualise the microglial response to 
metastatic breast tumour cells using intravital imaging. Using this approach, we demonstrate 
that activated microglia accumulate at the lesion site, giving rise to peritumoral cortical 
disorganisation. Although the immune response rapidly cleared the majority of tumour cells 
in this model, there was aberrant spontaneous activity both within the lesion and 
peritumorally. Further work is required to establish the role of microglial activation in the 
generation of altered excitability and seizure activity in the context of breast cancer 
metastasis to the brain. 
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Figure Legends 
 
Figure 1. Interactions between activated microglia and metastatic breast carcinoma cells. 
(A) MDA-MB-231-DsRed cells were implanted under the imaging window in Cx3cr1GFP/+ 
mice as described in Methods, mice allowed to recover, and cells visualised under 
anaesthesia using adapted multiphoton microscope. (B) Representative images of activated 
microglia (green) and breast cancer cells (red) 5 (i) and 7 days post-implantation (ii). 
Asterisks in main image indicate cells in 2X magnified images on right. Scale bars, 50 µm 
and 25 µm, respectively. Arrowheads indicate direct interactions between microglia and 
tumour cells. Arrows indicate elongate neurite-like processes on tumour cells. (C) Example 
cellular interactions from additional mice 5 (i) and 7 days post-implantation (ii). (D) Number 
of microglial interactions per cancer cell 5 and 7 days post-implantation (n = 8 fields of 
view/time point). (E) Density of GFP-positive cells in the presence/absence of cancer cells (n 
≥ 5 fields of view/time point). (F) Sholl analysis plot of microglia imaged from mice in which 
cancer cells had been implanted compared to mice in which no cancer cells had been 
implanted (n ≥ 20 cells/group). (G) Maximum branch length (µm) of microglia imaged from 
mice in which cancer cells had been implanted compared to mice in which no cancer cells 
had been implanted (n ≥ 20 cells/group). (H) Schoenen ramification index of microglia 
imaged from mice in which cancer cells had been implanted compared to mice in which no 
cancer cells had been implanted (n ≥ 20 cells/group). Box plots show median, 25th and 75th 
percentile values; whiskers are minimum and maximum values. **P < 0.01; ***P < 0.001; 
Mann-Whitney test for (D) and Kruskal-Wallis with Dunn’s post hoc test for (E), (G) and (H). 
 
Figure 2. Persistent accumulation of microglia at the tumour site for 13 days following 
implantation. Microglia (green) and tumour cells (red) were visualised under anaesthesia 
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using adapted multiphoton microscope at 5 (A), 9 (B), and 13 (C) days following 
implantation. Scale bar, 50 µm. Arrows indicate periphery of lesion where microglia have 
accumulated. Arrowheads indicate tumour cells within lesion, which are no longer visible 
after 9 days. (D) Number of DsRed-positive cells 5, 9 and 13 days post-implantation (n = 8 
fields of view/time point). ***P < 0.001; Kruskal-Wallis with Dunn’s post hoc test. 
 
Figure 3. Tumour cells are retained superficially but not deeper into the brain parenchyma. 
Confocal images at 20x (A) and 63x (B, C) of microglia (green), tumour cells (red) and nuclei 
(blue) in coronal sections obtained from Cx3cr1GFP/+ mice killed 22 days following 
implantation of MDA-MB-231-DsRed cells under the imaging window. Scale bars, 50 µm. 
Arrowheads indicate presence of viable DsRed-expressing tumour cells on outer surface of 
pia mater. Arrows indicate DsRed signal adjacent to, or within, GFP-expressing microglia 
deeper into brain parenchyma. 
 
Figure 4. Absence of human nuclear antigen-positive cells at the lesion site. Confocal image 
at 20x of microglia (green), human nuclear antigen (HNA; magenta) and nuclei (blue) in 
coronal section obtained from a Cx3cr1GFP/+ mouse killed 6 days following implantation of 
tumour cells under the imaging window. A positive control MDA-MB-231 orthotopic 
mammary xenograft tumour section showed strong HNA staining (data not shown). Scale 
bar, 50 µm. 
 
Figure 5. Presence of TMEM119-positive microglia at the lesion site. Confocal images at 
63x of TMEM119-positive microglia (magenta) and nuclei (blue) in coronal section obtained 
from a Cx3cr1GFP/+ mouse killed 6 days following implantation of tumour cells under the 
imaging window. (A) Control parenchyma away from lesion site. (B) Lesion site underneath 
location of imaging window. Scale bar, 50 µm. 
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Figure 6. Infiltration of CD45hi cells at the lesion site. (A, B) Confocal images at 63x of GFP-
positive microglia (green), CD45 (magenta) and nuclei (blue) in coronal section obtained 
from a Cx3cr1GFP/+ mouse killed 6 days following implantation of tumour cells under the 
imaging window. (A) Control parenchyma away from lesion site. (B) Lesion site underneath 
location of imaging window. A positive control naïve spleen section showed strong CD45 
staining (data not shown). Scale bar, 50 µm. 
 
Figure 7. Basic properties of lesion-associated extracellular spikes. (A) 25 s example of 
spontaneous, transient spike generation in superficial layers (cortical layer 2, L2) on the side 
of the brain ipsilateral to the tumour cell implantation site. Note concurrent recordings from 
deep (cortical layer 5, L5) layers demonstrated no spiking. (B) Example L2 recordings 
demonstrating the variability of spike generation. Illustrated are an example of the most 
common discharge – pairs of field spikes or relatively broad halfwidth and an example of a 
narrow halfwidth initial spike leading to a polyspike-like pattern of afterdischarge. Graph 
shows distribution of initial spike halfwidths (normalised to maximum incidence) for 138 
spontaneous events from n=4 slices from N=2 mice. Note the multimodal nature of the 
distribution of spike widths. (C) Spikes were highly localised annularly around the radial 
walls of the lesions in L2. Cartoon illustrates four recording sites at different positions from 
the core of the lesion in L2. Example traces taken from each of these positions reveal multi-
unit activity only within the body of the lesion, multiunit and field spike at the border of the 
lesion and field spike only extending <200 µm tangentially from this. Scale bars 0.1 mV, 2 s 
(A), 0.5 s (B), 0.1 s (C). 







Supplementary Table 1. Summary of Sholl analysis results from animals imaged in vivo 
and post mortem. 
Parameter Depth (µm) Post mortem In vivo P value1 
Maximum number 
of 
intersections/radius 
150 10.5 ± 0.8 8.5 ± 0.6 0.12 
250 9.9 ± 1.0 9.5 ± 0.5 0.95 
350 8.2 ± 0.5 8.7 ± 0.4 0.96 
Maximum branch 
length (µm) 
150 49.4 ± 5.2 28.8 ± 2.6 < 0.001 
250 39.0 ± 2.0 35.8 ± 3.6 0.88 
350 39.2 ± 2.7 36.6 ± 2.6 0.96 
Ramification index 150 2.2 ± 0.3 1.8 ± 0.1 0.35 
250 2.1 ± 0.3 2.1 ± 0.1 0.99 
350 1.8 ± 0.2 1.9 ± 0.1 0.96 
1Two-way ANOVA (n ≥ 10 cells/group). 
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Supplementary Figure 1. Effect of InverterScope on laser power and emission intensity. (A) 
Laser power at 488 nm and 920 nm exiting the objective with and without the InverterScope, 
measured at the indicated transmission percentages using a Coherent Fieldmate power 
meter. (B) AlexaFluor 488 phalloidin emission intensity in a standard sample imaged with 
and without the InverterScope: (i, ii) 488 nm excitation (40 mW) with 500-550 nm emission 
directed to the internal detectors. (iii, iv) 920 nm 2-photon excitation (13 mW) with 500-550 
nm emission directed to the non-descanned detectors. i,iii show a cell without the 
InverterScope and ii,iv show the same cell with the InverterScope. (C) Mean intensity 
measured within a defined region of interest (white box). ***P < 0.001, ANOVA with Sidak’s 
multiple comparisons test. Scale bar, 20 µm. Data are mean ± SD. 
 
Supplementary Figure 2. Post mortem visualisation of GFP-expressing microglia through a 
cranial imaging window. (A) Cx3cr1GFP/+ mice were euthanised, imaging window implanted 
as described in Methods, and microglia visualised using adapted multiphoton microscope. 
(B) Representative images of microglia at various distances below the imaging window: 150 
µm (i), 200 µm (ii), 250 µm (iii), 300 µm (iv), 350 µm (v). (vi), microglia in a coronal section of 
layer 2/3 cortex from a wildtype mouse labelled with anti-Iba1 antibody. Scale bar, 100 µm. 
Insets: 3X magnification; scale bar, 30 µm. (C) Sholl analysis plot of microglia imaged at the 
indicated depths below the imaging window (n = 10 cells/group). (D) Maximum branch length 
(µm) of microglia imaged at the indicated depths (n = 10 cells/group). (E) Schoenen 
ramification index of microglia at the indicated depths (n = 10 cells/group). Laser power was 
6 mW for depths 150 µm – 250 µm, and 10 mW at 300 µm and 350 µm. Box plots show 
median, 25th and 75th percentile values; whiskers are minimum and maximum values.  
 
Supplementary Figure 3. GFP-expressing microglia are ramified in healthy mice in vivo. (A) 
Imaging window was implanted in Cx3cr1GFP/+ mice as described in Methods, mice allowed 
to recover, and microglia visualised under anaesthesia using adapted multiphoton 
microscope. (B) Representative images of microglia at various distances below the imaging 
window: 150 µm (i), 250 µm (ii), 350 µm (iii). Scale bar, 100 µm. Insets: 3X magnification; 
scale bar, 30 µm. (C) Sholl analysis plot of microglia imaged at the indicated depths below 
the imaging window (n = 10 cells/group). (D) Maximum branch length (µm) of microglia 
imaged at the indicated depths (n = 10 cells/group). (E) Schoenen ramification index of 
microglia at the indicated depths (n = 10 cells/group). Box plots show median, 25th and 75th 
percentile values; whiskers are minimum and maximum values. 
 
Supplementary Figure 4. 3D reconstruction of Z stack image of microglia and breast 
cancer cells. Microglia (green) were visualised under anaesthesia using adapted multiphoton 
microscope 7 days following implantation of DsRed-expressing tumour cells (red). Scale bar, 
50 µm. 
 
Supplementary Figure 5. Presence of Iba1-positive microglia at the lesion site. Confocal 
images at 63x of Iba1-positive microglia (magenta) and nuclei (blue) in coronal section 
obtained from a Cx3cr1GFP/+ mouse killed 6 days following implantation of tumour cells under 
the imaging window. (A) Control parenchyma away from lesion site. (B) Lesion site 
underneath location of imaging window. Scale bar, 50 µm. 
 
Supplementary Figure 6. Lack of effect of Matrigel on microglial morphology. Microglia 
(green) were visualised under anaesthesia using adapted multiphoton microscope at 5, 9, 
and 13 days following implantation of Matrigel alone without tumour cells. Scale bar, 50 µm. 
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